Using NAD(P)H-Glo™ for
High-throughput Screening
and Drug Discovery
Dr. Stuart McElroy discusses use of the NAD(P)H-Glo™ Assay at BioAscent
Dr Stuart McElroy is director of the biosciences team at BioAscent. BioAscent provide pre-clinical drug discovery services, including de novo assay development, target analysis and bespoke screening strategies, chemistry, compound screening and compound management. The biosciences team conduct assay development and drug screening, followed by profiling for mechanism of action and cellular efficacy.
In this project, Dr McElroy and his team used the NAD(P)H-Glo™ Assay to screen 50,000 compounds against a poorly characterised enzyme that is a potential drug target. NAD(P)H-Glo was chosen as it has high sensitivity, with a wide dynamic range and high signal-to-background ratios. The bioluminescent mechanism of action of the assay enables screening of compounds which may auto-fluoresce and could give false positive results if screened using a fluorescent assay.
NAD(P)H-Glo is a bioluminescent, homogeneous, single-reagent-addition assay that quantitatively monitors the concentration of the reduced forms of NADH and NADPH levels in enzymatic reactions. The oxidised forms, NAD+ and NADP+, are not detected and do not interfere with quantitation.
Learn More About the NAD(P)H-Glo™ Assay
See All Energy Metabolism Assays
